• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » US FDA rolls out expedited access program for medical devices

US FDA rolls out expedited access program for medical devices

April 15, 2015 By MassDevice

Emergo Group

By Stewart Eisenhart, Emergo Group

US medical device market regulators are launching a new expedited market access program for select high-risk devices targeting life-threatening diseases or ailments.

First proposed in early 2014, the Expedited Access Pathway (EAP) is open to devices normally subject to Premarket Approval (PMA) or de novo registration but that can benefit patients suffering from otherwise hard-to-treat afflictions; for devices that qualify for EAP, Food and Drug Administration officials work with manufacturers to reduce timeframes and costs associated with market authorization in order to bring these products to market faster in the US.

Sponsored by Emergo Group

Qualifying devices go through priority and more interactive FDA review, and are also assigned FDA case managers. How extensive EAP features are for registrants, however, depends on the availability of agency resources – something manufacturers should keep in mind when deciding whether to sign up for EAP review.

How does a device qualify for EAP?

Medical devices that would either require PMA or de novo applications may qualify for EAP participation provided they’re intended to treat or diagnose life-threatening or irreversibly debilitating diseases or conditions. Qualifying devices must also meet one of four additional criteria:

  • No alternative treatment or diagnostic tool for the disease exists
  • The device uses novel technology that provides greater clinical benefit than currently used technology
  • The device itself provides greater clinical benefit than existing alternative means of treatment or diagnosis
  • The device’s availability serves patients’ best interest

Finally, EAP applicants must submit draft data development plans deemed acceptable by FDA reviewers.

Ideally, manufacturers interested in EAP should contact the FDA while developing their devices, before requesting Investigational Device Exemption (IDE) pivotal studies. Preparing for EAP applications during product development ensures that data collected in IDE studies can also be used in manufacturers’ market authorization submissions.

What to include in an EAP application

To request participation in EAP, a manufacturer should submit a Pre-Sub requesting EAP designation to the FDA’s Center for Devices and Radiological Health (CDRH) or Center for Biologics Evaluation and Research (CBER).

Pre-Sub requests should include cover letters, device descriptions, proposed intended use and indications for use statements, and draft data development plans that should contain the following components:

  • Data collection plan description and summary, including study synopsis and design
  • Outline of planned and/or completed clinical and nonclinical testing
  • Summaries of completed clinical and/or nonclinical studies
  • Proposed pre- and post-market data collection plans

The FDA plans to notify applicants within 30 days whether they qualify for EAP designation, or to request any additional information needed to make a final decision. According to the agency, special attention will be paid to how applicants plan to manage their post-market data collection, which may reduce pre-market data requirements and thus speed up applicants’ market authorization.

The FDA will start accepting applications for EAP participation April 15, 2015. Once the new program gets underway, an actual track record of by how much – or whether – EAP provides speedier US market access than standard PMA or de novo pathways.

Stewart Eisenhart covers medical device regulatory affairs for Emergo Group.

Filed Under: Emerging Markets, News Well, Regulatory/Compliance Tagged With: Emergo Group

In case you missed it

  • CeQur raises $115M for wearable insulin delivery device
  • Survey shows solid medical device industry performance despite pandemic
  • Cardinal Health wins $58M federal PPE contract
  • SentiAR closes $5.1M Series A
  • Endologix acquires PQ Bypass
  • Could BrainCheck’s simple test help COVID long-haulers?
  • Feds halt J&J COVID-19 vaccine due to blood clot concern
  • BioCorp, Roche launch Mallya smart insulin pen in France
  • The top 5 pharma firms by reputation
  • Famed marathoner uses Abbott glucose sensor for training
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
  • DiaSorin to buy Luminex for $1.8B
  • Genentech wins FDA approval for Xolair prefilled syringe
  • FDA slaps Class I label on rapid infuser recall
  • Microsoft spending $19.7B on Nuance and its AI for healthcare providers
  • Memic raises $96M to support surgical robot with humanoid-shaped arm
  • Heater-Cooler suit against LivaNova revived

RSS From Medical Design & Outsourcing

  • Micro to add plant in Costa Rica
    Contract manufacturer Micro today announced plans to open a new plant in Costa Rica. The 32,000 ft² facility will significantly increase Micro’s cleanroom assembly capacity, according to the Somerset, N.J.-based company. It will be located in the Zona Franca Metro business park and is expected to open in late 2021 with operations beginning in 2022.… […]
  • Survey shows solid medical device industry performance despite pandemic
    By Stewart Eisenhart, Emergo Group Medical device and IVD manufacturers report healthy performance over the course of 2020, but also faced significant operational and regulatory challenges related to the coronavirus pandemic. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not… […]
  • Cardinal Health wins $58M federal PPE contract
    Cardinal Health (NYSE: CAH) today said it has won a $57.8 million contract from the U.S. Dept. of Health and Human Services to support the Strategic National Stockpile. The Dublin, Ohio-based company received the contract, which includes options that if exercised by the HHS could reach $91.6 million, to store and distribute 80,000 pallets of… […]
  • Qosina adds single-use bioprocessing devices
    Qosina this week launched its product line for the single-use bioprocess industry. The new product line includes tube-to-tube bard connectors, luer fittings, check valves, tubing pinch clamps, tubing, steam thru connectors and more. Get the full story on our sister site, Medical Tubing + Extrusion. The post Qosina adds single-use bioprocessing devices appeared first on […]
  • Could BrainCheck’s simple test help COVID long-haulers?
    BrainCheck‘s eponymous mobile neurocognitive test can detect dementia and concussion. But it has a new application: post-COVID brain fog. Developed by neurologists at Baylor College of Medicine’s Eagleman Laboratory for Perception and Action, BrainCheck carries an FDA Class II Software as a Medical Device (SaMD) designation and can be used on a tablet or laptop… […]
  • XL Precision Technologies holding an April 28 webinar about laser tech
    XL Precision Technologies is holding an online webinar on April 28 at 8 a.m. Eastern time (1 p.m. U.K. time) about laser technology in medical device manufacturing. Register for the webinar here: https://bit.ly/XL-MER-Webinar2 Stockton-on-Tees, U.K.–based XL Precision Technologies provides laser welding, laser cutting of fine tubes and flat material and laser etching of components. It’s… […]
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
    Medtech companies paid $3.62 billion for access to physicians — 10% more than drug companies did — from 2014 to 2017, according to new research. Device company payments to surgical specialists were significantly more tied to the surgeons’ Medicare billing than payments from drug companies to specialists, according to the study, which appears in the… […]
  • FDA slaps Class I label on rapid infuser recall
    The FDA today declared that the recall of an emergency infusion device kit is the most serious type. The recall covers three models of disposable sets made by Smisson-Cartledge Biomedical for its ThermaCor 1200 rapid infuser, which is used for fluid or bolus delivery. The system is made of a footswitch for hands-free fluid control,… […]
  • Cretex breaks ground on new plant north of Minneapolis
    Cretex Cos. last week broke ground on a new 245,000 ft2 medical device contract manufacturing plant in Brooklyn Park, Minn. Elk River, Minn.–based Cretex plans to complete facility construction by the end of the year. The company expects the facility by the end of 2022 to house its stamping, molding and tool design — and… […]
  • Resonetics to expand manufacturing in Costa Rica
    Resonetics announced today it has leased new manufacturing space in Costa Rica to more than double its production there. The space, in a building near its current site in the Coyol Free Zone business park in Alajuela, will be expanded and reconfigured to create a 45,000 ft² production site. The move comes after the company… […]
  • Are Black patients not getting LVADs as quickly as white patients?
    Researchers from the University of Missouri conducted a study that found disparities in treating Black and white patients with advanced heart failure. According to a news release, the study found that Black patients with advanced heart failure were more likely to receive a left ventricular assist device (LVAD) — a pump implanted into the chest… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS